TEVA

TEVA Stock Forecast: Teva Pharmaceutical Industries Ltd. Price Predictions for 2026-2027

Last close, 23 Sept 2026

$39

Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 97 of 100 as at 23 Sept 2026 — among the strongest tenth.

Market cap

—

Ticker Nerd rank

97 / 100

Median analyst target

—

Analysts covering

—

Ticker Nerd rank

TEVA stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Teva Pharmaceutical Industries Ltd. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 23 Sept 2026

97 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Momentum

Quality

Value

Volatility

Accruals

Issuance

Revisions

Growth

Size

Momentum (97): The shares have been drifting up relative to others.

Growth (67): Sales and profits are flat, shrinking, or growing more slowly than they were.

Size (6): Larger than most of the companies we track — more scrutinised, less often mispriced.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

TEVA stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on TEVA, reported as data — targets and ratings, the market's view beside the model's.

We don’t hold enough price history for this company yet.

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. TEVA appears on the weeks it earns a place.

Estimates

TEVA analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Fundamentals

Teva Pharmaceutical Industries Ltd. (TEVA) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation

Trailing P/E: —
Price / sales: —
Price / book: —
EV / EBITDA: —

Growth & margins

Revenue growth (YoY): —
Earnings growth (YoY): —
Gross margin: —
Operating margin: —
Net margin: —

Returns & dividend

Return on equity: —
Return on assets: —
Dividend yield: —

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Teva Pharmaceutical Industries Ltd. (TEVA) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

Peers

TEVA vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Teva Pharmaceutical Industries Ltd. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest TEVA news & analysis

Teva to Host Conference Call to Discuss Third Quarter 2026 Financial Results on November 3, 2026 at 8 a.m. ET

GlobeNewsWire · 23 Sept 2026neutral

Teva announced it will release its third quarter 2026 financial results on Tuesday, November 3, 2026, at 7:00 a.m. ET, followed by a conference call and live webcast at 8:00 a.m. ET the same day. The announcement was made on September 23, 2026.

Why it matters — A Teva watcher would care because the scheduled earnings release and conference call provide the scheduled date for investors to hear the company's third quarter 2026 financial performance directly from management.

Teva Releases Q3 2026 Aide Memoire

GlobeNewsWire · 23 Sept 2026neutral

Teva Pharmaceutical Industries Ltd. announced that its Q3 2026 Aide Memoire is now available on the "Investors" page of its website. The company made the announcement on Sept. 23, 2026.

Why it matters — TEVA watchers can access the company's Q3 2026 financial reference material directly from its investor relations page.

Teva Pharmaceutical Industries Limited (TEVA) Presents at Bank of America Global Healthcare Conference 2026 Transcript

Seeking Alpha · 23 Sept 2026neutral

Teva Pharmaceutical Industries presented at the Bank of America Global Healthcare Conference 2026, with a transcript of the presentation published by Seeking Alpha. The company participated as a featured speaker at the industry conference.

Why it matters — A conference presentation gives TEVA watchers direct insight into management's latest commentary on strategy and operations.

Teva Eyes New Growth Phase After Securing Investment-Grade Ratings

MarketBeat · 23 Sept 2026neutral

Teva's President and CEO Richard Francis said at the BofA Global Healthcare Conference that the company is planning for greater financial flexibility after receiving investment-grade ratings from all three major credit rating agencies, signaling a new growth phase.

Why it matters — TEVA watchers would care because investment-grade ratings from all three major agencies could enhance the company's borrowing capacity and financial flexibility for future growth initiatives.

Teva Pharmaceutical Industries Limited (TEVA) Presents at U.S. All Stars Conference Transcript

Seeking Alpha · 22 Sept 2026neutral

Teva Pharmaceutical Industries Limited presented at the U.S. All Stars Conference, with a transcript of the presentation published by Seeking Alpha. The item announces the company's participation in the conference.

Why it matters — TEVA watchers may find the transcript of this conference presentation relevant to understanding management's current commentary and positioning.

FAQ

Frequently asked questions about TEVA stock

How does Ticker Nerd's model rank TEVA?

As at 23 Sept 2026, Teva Pharmaceutical Industries Ltd. ranks 97 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Momentum (97 of 100).

What is the TEVA stock forecast for 2030?

No analyst covering Teva Pharmaceutical Industries Ltd. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for TEVA are extrapolating price history, which says nothing about the business.

What is the latest news on TEVA?

The most recent item we track (GlobeNewsWire, 23 Sept 2026): "Teva to Host Conference Call to Discuss Third Quarter 2026 Financial Results on November 3, 2026 at 8 a.m. ET". Teva announced it will release its third quarter 2026 financial results on Tuesday, November 3, 2026, at 7:00 a.m. ET, followed by a conference call and live webcast at 8:00 a.m. ET the same day. The announcement was made on September 23, 2026.